INNOVATIVE RESEARCH IN SCIENCE
International scientific-online conference
12
THERAPEUTIC APPROACHES IN ANKYLOSING SPONDYLITIS:
CHALLENGES AND EVOLVING TREATMENT PARADIGMS
Abdujabborov Jamshidbek
Omonov Jamshid
Tursunboev Ulugbek
Kushboeva Shabnam
Abdurakhmanova Sayyora
https://doi.org/10.5281/zenodo.15192820
Introduction.
Ankylosing spondylitis (AS) is a chronic autoimmune
disorder that primarily affects the spine and the lumbosacral joints, leading to
their ankylosis and, eventually, disability. Characterized by inflammation and
progressive damage, AS predominantly impacts individuals under 40 years of
age, with a higher prevalence in men. The disease is associated with the human
leukocyte antigen HLA-B27, a genetic marker that plays a crucial role in its
pathogenesis. AS is recognized for its significant societal impact, as it often leads
to early disability in the younger population, affecting their quality of life and
productivity. Recent updates in therapeutic guidelines emphasize the
combination of non-pharmacological and pharmacological interventions to
manage disease progression and alleviate symptoms. This paper explores the
current treatment options for AS, focusing on the effectiveness and safety of
non-steroidal anti-inflammatory drugs (NSAIDs), biologic therapies, and newer
immunomodulatory agents, as well as the need for updated treatment
guidelines.
Materials and Methods.
The research for this mini-thesis is based on an
extensive review of current literature and clinical studies surrounding the
treatment of AS. Studies were selected from internationally recognized medical
journals, focusing on the therapeutic strategies employed in managing AS,
including pharmacological treatments such as NSAIDs, disease-modifying
antirheumatic drugs (DMARDs), biologic therapies, and the newer targeted
drugs, such as Janus kinase (JAK) inhibitors and IL-17 inhibitors. The review
methodology included an analysis of clinical trials and meta-analyses, with
particular attention given to the efficacy and safety profiles of these treatment
modalities. Research from the Spondyloarthritis International Society (ASAS),
European League Against Rheumatism (EULAR), and American College of
Rheumatology (ACR) guidelines were incorporated to assess the evolution of
therapeutic recommendations. This paper also synthesizes expert opinions and
emerging data on the use of biological therapies and the potential need for more
individualized treatment plans in light of patient response variability.
INNOVATIVE RESEARCH IN SCIENCE
International scientific-online conference
13
Results.
The findings from the review of current literature reveal a shift in
the management paradigm of AS, highlighting the growing role of biologic
therapies and targeted immunomodulation. NSAIDs remain the first-line
treatment for AS, helping to alleviate pain and inflammation. However, their
long-term use raises concerns due to serious side effects such as gastric ulcers,
liver toxicity, and cardiovascular issues. Despite these risks, NSAIDs continue to
be a cornerstone of initial treatment, often prescribed on a long-term, daily basis
to manage disease activity.
For patients who do not respond to NSAIDs, second-line therapies include
biologic agents, such as TNF-α inhibitors (e.g., adalimumab, infliximab) and IL-
17 inhibitors (e.g., secukinumab, ixekizumab). These biologics have shown
significant efficacy in reducing disease activity, improving mobility, and slowing
disease progression. The introduction of IL-17 inhibitors has been particularly
noteworthy, as these agents target a key pro-inflammatory cytokine involved in
the pathogenesis of AS. Studies have demonstrated that IL-17 inhibitors can
reduce the activity of AS, as well as prevent radiological damage to the spine and
joints, with favorable safety profiles.
Janus kinase (JAK) inhibitors, such as tofacitinib, filgotinib, and
upadacitinib, represent a new class of drugs that have shown promising results
in treating refractory AS. A 12-week study on filgotinib demonstrated a 33%
reduction in AS disease activity among NSAID-refractory patients. However,
concerns regarding the safety of JAK inhibitors remain, with adverse events
reported in clinical trials, although no major safety concerns have been
identified.
The effectiveness of sulfasalazine, a traditional DMARD, remains under
debate. While some studies suggest its moderate efficacy in treating the
peripheral form of AS, other evidence points to its effectiveness in both axial and
peripheral forms of the disease. However, its role as a second-line therapy is less
pronounced compared to biologics and JAK inhibitors.
The most striking recent development is the dual inhibition of IL-17A and
IL-17F through bimekizumab, which has shown rapid and sustained
improvements in key AS indicators, with over 60% of patients achieving an
ASAS40 response at 320 mg. These results underscore the growing importance
of IL-17 inhibitors in the therapeutic landscape of AS.
Conclusion.
In conclusion, the management of ankylosing spondylitis has
evolved significantly over the past decades, with considerable advancements in
pharmacological therapies. The updated treatment guidelines emphasize a
INNOVATIVE RESEARCH IN SCIENCE
International scientific-online conference
14
combination of non-pharmacological approaches, such as exercise therapy, and
pharmacological treatments, including NSAIDs, DMARDs, and biologic therapies.
While biologics such as TNF-α inhibitors and IL-17 inhibitors have
revolutionized AS treatment, there remain concerns about the safety profiles of
long-term NSAID use and the emerging data on newer agents like JAK inhibitors.
Given the complexity and variability of treatment responses, it is crucial
that treatment plans be tailored to individual patients, considering both efficacy
and safety. Furthermore, the evolving evidence calls for the modernization of
international treatment guidelines to incorporate the latest therapeutic
advancements. Future research should focus on optimizing drug regimens,
assessing the long-term effects of new therapies, and investigating the impact of
AS treatments during the COVID-19 pandemic. As the understanding of AS
continues to deepen, more personalized and effective treatment options are
expected to emerge, improving the quality of life for patients with this
debilitating condition.
References:
1.
Turaev, S. Z. I., & Rakhimov, S. (2023). ASSESSMENT OF THE QUALITY OF
LIFE IN PATIENTS WITH CHRONIC KIDNEY DISEASE IN THE PRACTICE OF
HEMODIALYSIS. Journal of Modern Educational Achievements, 6(6), 103- 109.
2.
Rakhimova, M. B., Akhmedov, K. S., Rakhimov, S. S., & Zaripov, S. I. (2023).
Extrasceletal Manifestations in Patients with Ankylosing Spondylitis. Journal of
Coastal Life Medicine, 11, 1315-1321.
3.
S. I. Zaripov and N. M. B. Abdurakhmanova, "The Relationship Between
Systemic Sclerosis and Anti-Fibrillarin Antibodies," Journal of Modern
Educational Achievements, vol. 6, no. 6, pp. 235-238, 2024.
4.
Z. S. Istamovich, A. K. Sadullayevich, and A. N. Mirza-Bakhtiyarkhanovna,
"The Significance of Autoantibodies in the Pathogenesis of Systemic Sclerosis
(Literature Review)," Journal of Biomedicine and Practice, vol. 8, no. 2, 2023
5.
S. I. Zaripov, I. A. Turaev, and S. S. Rakhimov, "Quality of Life in Patients
with Chronic Kidney Disease Receiving Program Hemodialysis and Possible
Ways of Its Correction," Uzbek Medical Journal, vol. 3, no. 5, 2022.
6.
Rakhmatov, A. M., & Zaripov, S. I. (2024). GOUT AND ITS ASSOCIATION
WITH GOUTY NEPHROPATHY: AN ANALYSIS OF 46 PATIENTS. В CURRENT
APPROACHES AND NEW RESEARCH IN MODERN SCIENCES (Т. 3, Выпуск 16, сс.
100–102).
7.
Akhmedov, K. S., Rixsiyeva, L. M., et al. (2023). Changes in c-telopeptide
collagen-ii level in patients with ankylosing spondyloarthritis after COVID-19.
Journal of Modern Educational Achievements, 3(3), 78-87.
INNOVATIVE RESEARCH IN SCIENCE
International scientific-online conference
15
8.
Norbutoev O, Akhmedov K, Abdurakhmanova N, et al. Treatment and
Genotypic Characteristics of Patients with Rheumatoid Arthritis. BIO Web of
Conferences. 2025;151:04030.
9.
Ikhtiyor Turaev. (2024). Comparative Efficacy of Biologic Vs. Non-Biologic
Therapies in Reactive Arthritis: a 52-Week Cohort Study. International Journal of
Scientific Trends, 3(12), 124–128
10. I.A. T. CURRENT APPROACHES TO TREATMENT OF CHRONIC KIDNEY
DISEASE COMPLICATED NEPHROGENIC HYPERTENSION. Zenodo. 2023.
Available at: https://zenodo.org/records/10091454
11. Axmedov Kh.S., Turayev I.A., Khalmetova F.I., Zaripov S.I. The role of IL-17
inhibitors in the treatment of reactive arthritis. 2024. Available at:
https://repo.tma.uz/xmlui/handle/1/358
12. Axmedov Kh.S, Abdurakhmanova N.M, Zaripov S.S., & Turaev I.A. (2023).
THE EFFECT OF CLIMATE-GEOGRAPHICAL FACTORS ON RHEUMATOID
ARTHRITIS ACTIVITY. World Bulletin of Public Health, 18, 67-69.
13. Khalmurad Akhmedov, Sagdiyana Buranova, Ikhtiyor Turaev. (2023).
RETROSPECTIVE ASSESSMENT OF JOINT SYNDROME AND JOINT STRUCTURE
DISORDERS IN OSTEOARTHRITIS. Galaxy International Interdisciplinary
Research Journal, 11(3), 79–85
14. Rano K.Dadabaeva, Elnora A.Abduganieva, Kenesh O.Djusupov, Indrani
Kalkan, & Oybek F.Eshmamatov. (2025). Comparative Characteristics Of Body
Composition In Obesity Phenotypes. Texas Journal of Medical Science, 42, 29–35.
15. Gadaeva Nilufar, Turakulov Rustam, Eshankulov Sardor, Eshmamatov
Oybek, THE IMPORTANCE OF KLOTHO PROTEIN IN THE DIAGNOSIS OF
CHRONIC KIDNEY DISEASE. (2024). International Journal of Modern Medicine,
3(10), 46-59.
16. Rustam Turakulov, Oybek Eshmamatov. INFLUENCE OF ANEMIA ON THE
COURSE OF OBSTRUCTIVE PULMONARY DISEASE. INTERDISCIPLINE
INNOVATION AND SCIENTIFIC RESEARCH CONFERENCE. 2023;1(9):31–2.
17. Rano K. Dadabaeva, Oybek F. Eshmamatov, Zebo I. Ruzieva, & Ozoda A.
Mirzabekova. (2023). THE SIGNIFICANCE OF SIMULATION TRAINING FOR
FAMILY PHYSICIANS AS A TOOL FOR OBJECTIVE SELF-ASSESSMENT. Central
Asian Journal of Medicine, (1), 136-141
18. Mirzabekova O, Dadabaeva R, Nuriddinova F, et al. Morphological aspects
of hyalinomembrane disease of the newborn. BIO Web of Conferences. 65.
19. O.F E, R.I T, N.M. A. YURAK RЕSINXRONLASH AMALIYOTI O’TKAZILGAN
BЕMORLARDA EXOKARDIOGRAFIK KO’RSATKICHLARIGA QARAB KLINIK
INNOVATIVE RESEARCH IN SCIENCE
International scientific-online conference
16
HOLATINI SOLISHTIRIB BAHOLASH.
Zenodo. 2022. Available at:
https://zenodo.org/record/6026247
20. Эшмаматов О.Ф. Дадабаева Р.К., Курбонов А.К., Нуриддинова Ф.М.,
Кулкараев А.К. ЗНАЧЕНИЕ СИМУЛЯЦИОННОГО ОБУЧЕНИЯ СЕМЕЙНЫХ
ВРАЧЕЙ
КАК
ИНСТРУМЕНТ
ОБЪЕКТИВНОЙ
САМООЦЕНКИ.
КАЗАХСТАНСКИЙ ЖУРНАЛ МЕДИЦИНЫ И ФАРМАЦИИ. Т1б сс. 48-54
21. OF Eshmamatov, RI Turakulov. O ‘pkaning surunkali obstruktiv kasalligida
kamqonlikni uchrashi (2023) Вестник ТМА. Том 11, сс. 50-52
22. RK Dadabaeva, OF Eshmamatov. The value of simulation training in the
self-training of family doctors. СБОРНИК НАУЧНЫХ ТРУДОВ V
МЕЖДУНАРОДНОГО НАУЧНО-ПРАКТИЧЕСКОГО ФОРУМА «ПЕРСПЕКТИВЫ
РАЗВИТИЯ
ПЕРВИЧНОЙ
МЕДИКО–САНИТАРНОЙ
ПОМОЩИ
В
УЗБЕКИСТАНЕ, СЕГОДНЯ И ЗАВТРА» (2023)
23. OF Eshmamatov, RQ Qoraxonov. ЮРАК РЕСИНХРОНЛАШ АМАЛИЁТИ
ЎТКАЗИЛГАН
БЕМОРЛАРДА
ЖИСМОНИЙ
ЮКЛАМАЛАРГА
ЧИДАМЛИЛИКНИ БАҲОЛАШ. O'zbekiston terapiya axborotnomasi (2021)
24. RK Dadabayeva, AK Kulkarayev, FM Nuriddinova, OF Eshmamatov, NA
Axmedova, MS Tojiboyev. Aritmiya va blokadalarning taqqoslama tashxisi va
UASH taktikasi. Intellektual mulk agentligi (2022). Номер патента 005193
